{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:21:20Z","timestamp":1782602480984,"version":"3.54.5"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T00:00:00Z","timestamp":1553126400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s00059-019-4798-3","type":"journal-article","created":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T08:43:59Z","timestamp":1553157839000},"page":"210-217","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Congestive heart failure caused by silent ischemia and silent myocardial infarction","Kongestive Herzinsuffizienz durch stumme Isch\u00e4mie und stummen Herzinfarkt"],"prefix":"10.1007","volume":"44","author":[{"given":"P.","family":"Valensi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Meune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,21]]},"reference":[{"issue":"1","key":"4798_CR1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0002-9149(74)90089-7","volume":"34","author":"WB Kannel","year":"1974","unstructured":"Kannel WB, Hjortland M, Castelli WP (1974) Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 34(1):29\u201334","journal-title":"Am J Cardiol"},{"issue":"3","key":"4798_CR2","doi-asserted-by":"publisher","first-page":"612","DOI":"10.2337\/diacare.28.3.612","volume":"28","author":"IS Thrainsdottir","year":"2005","unstructured":"Thrainsdottir IS, Aspelund T, Thorgeirsson G et al (2005) The association between glucose abnormalities and heart failure in the population-based Reykjavik study. Diabetes Care 28(3):612\u2013616","journal-title":"Diabetes Care"},{"issue":"2","key":"4798_CR3","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/HJH.0b013e3283331169","volume":"28","author":"G Simone de","year":"2010","unstructured":"de Simone G, Devereux RB, Chinali M et\u00a0al (2010) Diabetes and incident heart failure in hypertensive and normotensive participants of the Strong Heart Study. J\u00a0Hypertens 28(2):353\u2013360. \n                    https:\/\/doi.org\/10.1097\/HJH.0b013e3283331169","journal-title":"J Hypertens"},{"issue":"11","key":"4798_CR4","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1161\/CIRCRESAHA.116.306924","volume":"118","author":"E Standl","year":"2016","unstructured":"Standl E, Schnell O, McGuire DK (2016) Heart failure considerations of antihyperglycemic medications for type 2 diabetes. Circ Res 118(11):1830\u20131843. \n                    https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.306924","journal-title":"Circ Res"},{"issue":"15","key":"4798_CR5","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1056\/NEJMoa1608664","volume":"376","author":"A Rawshani","year":"2017","unstructured":"Rawshani A, Rawshani A, Franzen S et\u00a0al (2017) Mortality and cardiovascular disease in type 1 and type 2 diabetes. N\u00a0Engl J Med 376(15):1407\u20131418. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1608664","journal-title":"N Engl J Med"},{"issue":"8","key":"4798_CR6","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1007\/s00125-012-2579-0","volume":"55","author":"LJ Boonman-de Winter","year":"2012","unstructured":"Boonman-de Winter LJ, Rutten FH, Cramer MJ et al (2012) High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes. Diabetologia 55(8):2154\u20132162. \n                    https:\/\/doi.org\/10.1007\/s00125-012-2579-0","journal-title":"Diabetologia"},{"issue":"6","key":"4798_CR7","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1053\/euhj.1998.1280","volume":"20","author":"MR Cowie","year":"1999","unstructured":"Cowie MR, Wood DA, Coats AJ et al (1999) Incidence and aetiology of heart failure; a\u00a0population-based study. Eur Heart\u00a0J 20(6):421\u2013428","journal-title":"Eur Heart J"},{"issue":"9","key":"4798_CR8","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.2337\/diacare.24.9.1614","volume":"24","author":"GA Nichols","year":"2001","unstructured":"Nichols GA, Hillier TA, Erbey JR, Brown JB (2001) Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care 24(9):1614\u20131619","journal-title":"Diabetes Care"},{"issue":"10166","key":"4798_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I et al (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a\u00a0systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393(10166):31\u201339. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(18)32590-X","journal-title":"Lancet"},{"issue":"3","key":"4798_CR10","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1464-5491.2010.03221.x","volume":"28","author":"W Dinh","year":"2011","unstructured":"Dinh W, Futh R, Lankisch M et\u00a0al (2011) Cardiovascular autonomic neuropathy contributes to left ventricular diastolic dysfunction in subjects with type 2 diabetes and impaired glucose tolerance undergoing coronary angiography. Diabet Med 28(3):311\u2013318. \n                    https:\/\/doi.org\/10.1111\/j.1464-5491.2010.03221.x","journal-title":"Diabet Med"},{"issue":"11","key":"4798_CR11","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1136\/hrt.2007.128769","volume":"94","author":"C Tribouilloy","year":"2008","unstructured":"Tribouilloy C, Rusinaru D, Mahjoub H et al (2008) Prognostic impact of diabetes mellitus in patients with heart failure and preserved ejection fraction: a\u00a0prospective five-year study. Heart 94(11):1450\u20131455. \n                    https:\/\/doi.org\/10.1136\/hrt.2007.128769","journal-title":"Heart"},{"issue":"1","key":"4798_CR12","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/ejhf.679","volume":"19","author":"G Targher","year":"2017","unstructured":"Targher G, Dauriz M, Laroche C et al (2017) In-hospital and 1\u2011year mortality associated with diabetes in patients with acute heart failure: results from the ESC-HFA Heart Failure Long-Term Registry. Eur J Heart Fail 19(1):54\u201365. \n                    https:\/\/doi.org\/10.1002\/ejhf.679","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"4798_CR13","doi-asserted-by":"publisher","first-page":"671","DOI":"10.2337\/dc16-2016","volume":"40","author":"M Dauriz","year":"2017","unstructured":"Dauriz M, Targher G, Laroche C et al (2017) Association between diabetes and 1\u2011year adverse clinical outcomes in a\u00a0multinational cohort of ambulatory patients with chronic heart failure: results from the ESC-HFA Heart Failure Long-Term Registry. Diabetes Care 40(5):671\u2013678. \n                    https:\/\/doi.org\/10.2337\/dc16-2016","journal-title":"Diabetes Care"},{"issue":"10","key":"4798_CR14","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1161\/CIRCULATIONAHA.114.014796","volume":"132","author":"MA Cavender","year":"2015","unstructured":"Cavender MA, Steg PG, Smith SC Jr et\u00a0al (2015) Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Circulation 132(10):923\u2013931. \n                    https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.014796","journal-title":"Circulation"},{"issue":"13","key":"4798_CR15","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.jacc.2016.06.061","volume":"68","author":"I Johansson","year":"2016","unstructured":"Johansson I, Dahlstrom U, Edner M et\u00a0al (2016) Prognostic implications of type 2 diabetes mellitus in Ischemic and nonischemic heart failure. J\u00a0Am Coll Cardiol 68(13):1404\u20131416. \n                    https:\/\/doi.org\/10.1016\/j.jacc.2016.06.061","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"4798_CR16","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.amjcard.2012.11.042","volume":"111","author":"YB Pride","year":"2013","unstructured":"Pride YB, Piccirillo BJ, Gibson CM (2013) Prevalence, consequences, and implications for clinical trials of unrecognized myocardial infarction. Am J Cardiol 111(6):914\u2013918. \n                    https:\/\/doi.org\/10.1016\/j.amjcard.2012.11.042","journal-title":"Am J Cardiol"},{"issue":"3","key":"4798_CR17","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.acvd.2010.11.013","volume":"104","author":"P Valensi","year":"2011","unstructured":"Valensi P, Lorgis L, Cottin Y (2011) Prevalence, incidence, predictive factors and prognosis of silent myocardial infarction: a\u00a0review of the literature. Arch Cardiovasc Dis 104(3):178\u2013188. \n                    https:\/\/doi.org\/10.1016\/j.acvd.2010.11.013","journal-title":"Arch Cardiovasc Dis"},{"issue":"1","key":"4798_CR18","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1093\/eurheartj\/ehp377","volume":"31","author":"DC Burgess","year":"2010","unstructured":"Burgess DC, Hunt D, Li L et\u00a0al (2010) Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Eur Heart\u00a0J 31(1):92\u201399. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehp377","journal-title":"Eur Heart J"},{"issue":"6","key":"4798_CR19","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.2337\/dc10-2398","volume":"34","author":"MR MacDonald","year":"2011","unstructured":"MacDonald MR, Petrie MC, Home PD et\u00a0al (2011) Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a\u00a0substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) Study. Diabetes Care 34(6):1394\u20131396. \n                    https:\/\/doi.org\/10.2337\/dc10-2398","journal-title":"Diabetes Care"},{"issue":"1","key":"4798_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacc.2017.10.071","volume":"71","author":"WT Qureshi","year":"2018","unstructured":"Qureshi WT, Zhang ZM, Chang PP et al (2018) Silent myocardial infarction and long-term risk of heart failure: the ARIC Study. J\u00a0Am Coll Cardiol 71(1):1\u20138. \n                    https:\/\/doi.org\/10.1016\/j.jacc.2017.10.071","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"4798_CR21","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.diabres.2008.06.016","volume":"82","author":"S Kondola","year":"2008","unstructured":"Kondola S, Davis WA, Dembo LG, Davis TM (2008) A cardiac magnetic resonance imaging study of electrocardiographic Q waves in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Res Clin Pract 82(1):87\u201392. \n                    https:\/\/doi.org\/10.1016\/j.diabres.2008.06.016","journal-title":"Diabetes Res Clin Pract"},{"issue":"12","key":"4798_CR22","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/j.jcmg.2018.02.009","volume":"11","author":"RP Amier","year":"2018","unstructured":"Amier RP, Smulders MW, van der Flier WM et al (2018) Long-term prognostic implications of previous silent myocardial infarction in patients presenting with acute myocardial infarction. JACC Cardiovasc Imaging 11(12):1773\u20131781. \n                    https:\/\/doi.org\/10.1016\/j.jcmg.2018.02.009","journal-title":"JACC Cardiovasc. Imaging"},{"key":"4798_CR23","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1159\/000418828","volume":"37","author":"WB Kannel","year":"1990","unstructured":"Kannel WB, Cupples LA, Gagnon DR (1990) Incidence, precursors and prognosis of unrecognized myocardial infarction. Adv Cardiol 37:202\u2013214. \n                    https:\/\/doi.org\/10.1159\/000418828","journal-title":"Adv Cardiol"},{"issue":"5","key":"4798_CR24","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/S1262-3636(07)70060-5","volume":"29","author":"E Cosson","year":"2003","unstructured":"Cosson E, Guimfack M, Paries J et\u00a0al (2003) Are silent coronary stenoses predictable in diabetic patients and predictive of cardiovascular events? Diabetes Metab 29(5):470\u2013476","journal-title":"Diabetes Metab"},{"issue":"2","key":"4798_CR25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.diabet.2010.01.001","volume":"36","author":"P Valensi","year":"2010","unstructured":"Valensi P, Cosson E (2010) It is not yet the time to stop screening diabetic patients for silent myocardial ischaemia. Diabetes Metab 36(2):91\u201396. \n                    https:\/\/doi.org\/10.1016\/j.diabet.2010.01.001","journal-title":"Diabetes Metab"},{"issue":"8","key":"4798_CR26","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.2337\/diacare.27.8.1954","volume":"27","author":"FJ Wackers","year":"2004","unstructured":"Wackers FJ, Young LH, Inzucchi SE et\u00a0al (2004) Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD Study. Diabetes Care 27(8):1954\u20131961","journal-title":"Diabetes Care"},{"issue":"10","key":"4798_CR27","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.jcmg.2014.07.010","volume":"7","author":"MJ Zellweger","year":"2014","unstructured":"Zellweger MJ, Maraun M, Osterhues HH et\u00a0al (2014) Progression to overt or silent CAD in asymptomatic patients with diabetes mellitus at high coronary risk: main findings of the prospective multicenter BARDOT trial with a\u00a0pilot randomized treatment substudy. JACC Cardiovasc Imaging 7(10):1001\u20131010. \n                    https:\/\/doi.org\/10.1016\/j.jcmg.2014.07.010","journal-title":"JACC Cardiovasc. Imaging"},{"issue":"9","key":"4798_CR28","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1111\/dme.13364","volume":"34","author":"A Sultan","year":"2017","unstructured":"Sultan A, Perriard F, Macioce V et al (2017) Evolution of silent myocardial ischaemia prevalence and cardiovascular disease risk factor management in type 2 diabetes over a\u00a010-year period: an observational study. Diabet Med 34(9):1244\u20131251. \n                    https:\/\/doi.org\/10.1111\/dme.13364","journal-title":"Diabet Med"},{"issue":"4","key":"4798_CR29","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/j.1464-5491.2004.01157.x","volume":"21","author":"E Cosson","year":"2004","unstructured":"Cosson E, Paycha F, Paries J et\u00a0al (2004) Detecting silent coronary stenoses and stratifying cardiac risk in patients with diabetes: ECG stress test or exercise myocardial scintigraphy? Diabet Med 21(4):342\u2013348. \n                    https:\/\/doi.org\/10.1111\/j.1464-5491.2004.01157.x","journal-title":"Diabet Med"},{"key":"4798_CR30","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1475-2840-13-20","volume":"13","author":"MT Nguyen","year":"2014","unstructured":"Nguyen MT, Pham I, Valensi P et al (2014) Flow-mediated-paradoxical vasoconstriction is independently associated with asymptomatic myocardial ischemia and coronary artery disease in type 2 diabetic patients. Cardiovasc Diabetol 13:20. \n                    https:\/\/doi.org\/10.1186\/1475-2840-13-20","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"4798_CR31","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.2337\/diab.42.7.1017","volume":"42","author":"A Nitenberg","year":"1993","unstructured":"Nitenberg A, Valensi P, Sachs R et al (1993) Impairment of coronary vascular reserve and ACh-induced coronary vasodilation in diabetic patients with angiographically normal coronary arteries and normal left ventricular systolic function. Diabetes 42(7):1017\u20131025","journal-title":"Diabetes"},{"issue":"2","key":"4798_CR32","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/eci.12389","volume":"45","author":"I Pham","year":"2015","unstructured":"Pham I, Nguyen MT, Valensi P et\u00a0al (2015) Noninvasive study of coronary microcirculation response to a\u00a0cold pressor test. Eur J Clin Invest 45(2):135\u2013143. \n                    https:\/\/doi.org\/10.1111\/eci.12389","journal-title":"Eur J Clin Invest"},{"issue":"9","key":"4798_CR33","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1016\/j.jacc.2003.09.068","volume":"43","author":"P Raggi","year":"2004","unstructured":"Raggi P, Shaw LJ, Berman DS, Callister TQ (2004) Prognostic value of coronary artery calcium screening in subjects with and without diabetes. J\u00a0Am Coll Cardiol 43(9):1663\u20131669. \n                    https:\/\/doi.org\/10.1016\/j.jacc.2003.09.068","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"4798_CR34","doi-asserted-by":"publisher","first-page":"e003528","DOI":"10.1161\/CIRCIMAGING.115.003528","volume":"9","author":"V Valenti","year":"2016","unstructured":"Valenti V, Hartaigh BO, Cho I et al (2016) Absence of coronary artery calcium identifies asymptomatic diabetic individuals at low near-term but not long-term risk of mortality: a 15-year follow-up study of 9715 patients. Circ Cardiovasc Imaging 9(2):e3528. \n                    https:\/\/doi.org\/10.1161\/CIRCIMAGING.115.003528","journal-title":"Circ Cardiovasc Imaging"},{"issue":"6","key":"4798_CR35","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1093\/eurheartj\/ehi808","volume":"27","author":"DV Anand","year":"2006","unstructured":"Anand DV, Lim E, Hopkins D et\u00a0al (2006) Risk stratification in uncomplicated type 2 diabetes: prospective evaluation of the combined use of coronary artery calcium imaging and selective myocardial perfusion scintigraphy. Eur Heart\u00a0J 27(6):713\u2013721. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehi808","journal-title":"Eur Heart J"},{"issue":"39","key":"4798_CR36","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1093\/eurheartj\/eht108","volume":"34","author":"L Ryden","year":"2013","unstructured":"Ryden L, Grant PJ, Anker SD et al (2013) ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart\u00a0J 34(39):3035\u20133087. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/eht108","journal-title":"Eur Heart J"},{"key":"4798_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcm.2018.09.004","author":"EZ Soliman","year":"2018","unstructured":"Soliman EZ (2018) Silent myocardial infarction and risk of heart failure: current evidence and gaps in knowledge. Trends Cardiovasc Med. \n                    https:\/\/doi.org\/10.1016\/j.tcm.2018.09.004","journal-title":"Trends Cardiovasc Med"},{"issue":"4","key":"4798_CR38","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.2337\/diacare.26.4.1313","volume":"26","author":"E Cosson","year":"2003","unstructured":"Cosson E, Guimfack M, Paries J et\u00a0al (2003) Prognosis for coronary stenoses in patients with diabetes and silent myocardial ischemia. Diabetes Care 26(4):1313\u20131314","journal-title":"Diabetes Care"},{"issue":"15","key":"4798_CR39","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1001\/jama.2009.476","volume":"301","author":"LH Young","year":"2009","unstructured":"Young LH, Wackers FJ, Chyun DA et\u00a0al (2009) Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a\u00a0randomized controlled trial. JAMA 301(15):1547\u20131555. \n                    https:\/\/doi.org\/10.1001\/jama.2009.476","journal-title":"JAMA"},{"issue":"9","key":"4798_CR40","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.2337\/dc11-0480","volume":"34","author":"E Cosson","year":"2011","unstructured":"Cosson E, Nguyen MT, Chanu B et\u00a0al (2011) Cardiovascular risk prediction is improved by adding asymptomatic coronary status to routine risk assessment in type 2 diabetic patients. Diabetes Care 34(9):2101\u20132107. \n                    https:\/\/doi.org\/10.2337\/dc11-0480","journal-title":"Diabetes Care"},{"issue":"2","key":"4798_CR41","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2337\/diacare.24.2.339","volume":"24","author":"P Valensi","year":"2001","unstructured":"Valensi P, Sachs RN, Harfouche B et\u00a0al (2001) Predictive value of cardiac autonomic neuropathy in diabetic patients with or without silent myocardial ischemia. Diabetes Care 24(2):339\u2013343","journal-title":"Diabetes Care"},{"issue":"3","key":"4798_CR42","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1053\/euhj.2000.2289","volume":"22","author":"KF Fox","year":"2001","unstructured":"Fox KF, Cowie MR, Wood DA et\u00a0al (2001) Coronary artery disease as the cause of incident heart failure in the population. Eur Heart\u00a0J 22(3):228\u2013236. \n                    https:\/\/doi.org\/10.1053\/euhj.2000.2289","journal-title":"Eur Heart J"},{"issue":"5","key":"4798_CR43","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s00380-015-0669-x","volume":"31","author":"T Kosuga","year":"2016","unstructured":"Kosuga T, Komukai K, Miyanaga S et\u00a0al (2016) Diabetes is a\u00a0predictor of coronary artery stenosis in patients hospitalized with heart failure. Heart Vessels 31(5):671\u2013676. \n                    https:\/\/doi.org\/10.1007\/s00380-015-0669-x","journal-title":"Heart Vessels"},{"issue":"4","key":"4798_CR44","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.diabet.2010.12.006","volume":"37","author":"MT Nguyen","year":"2011","unstructured":"Nguyen MT, Cosson E, Valensi P et\u00a0al (2011) Transthoracic echocardiographic abnormalities in asymptomatic diabetic patients: association with microalbuminuria and silent coronary artery disease. Diabetes Metab 37(4):343\u2013350. \n                    https:\/\/doi.org\/10.1016\/j.diabet.2010.12.006","journal-title":"Diabetes Metab"},{"key":"4798_CR45","doi-asserted-by":"publisher","first-page":"743503","DOI":"10.1155\/2015\/743503","volume":"2015","author":"I Pham","year":"2015","unstructured":"Pham I, Cosson E, Nguyen MT et\u00a0al (2015) Evidence for a\u00a0specific diabetic cardiomyopathy: an observational retrospective echocardiographic study in 656 asymptomatic type 2 diabetic patients. Int J Endocrinol 2015:743503. \n                    https:\/\/doi.org\/10.1155\/2015\/743503","journal-title":"Int J Endocrinol"},{"issue":"27","key":"4798_CR46","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD et\u00a0al (2016) 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart\u00a0J 37(27):2129\u20132200. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehw128","journal-title":"Eur Heart J"},{"issue":"3","key":"4798_CR47","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.ejheart.2004.01.010","volume":"6","author":"TA McDonagh","year":"2004","unstructured":"McDonagh TA, Holmer S, Raymond I et al (2004) NT-proBNP and the diagnosis of heart failure: a\u00a0pooled analysis of three European epidemiological studies. Eur J Heart Fail 6(3):269\u2013273. \n                    https:\/\/doi.org\/10.1016\/j.ejheart.2004.01.010","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"4798_CR48","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1111\/j.1464-5491.2009.02788.x","volume":"26","author":"E Cosson","year":"2009","unstructured":"Cosson E, Nguyen MT, Pham I et al (2009) N\u2011terminal pro-B-type natriuretic peptide: an independent marker for coronary artery disease in asymptomatic diabetic patients. Diabet Med 26(9):872\u2013879. \n                    https:\/\/doi.org\/10.1111\/j.1464-5491.2009.02788.x","journal-title":"Diabet Med"},{"issue":"14","key":"4798_CR49","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1016\/j.jacc.2017.07.792","volume":"70","author":"L Ernande","year":"2017","unstructured":"Ernande L, Audureau E, Jellis CL et\u00a0al (2017) Clinical implications of echocardiographic phenotypes of patients with diabetes mellitus. J\u00a0Am Coll Cardiol 70(14):1704\u20131716. \n                    https:\/\/doi.org\/10.1016\/j.jacc.2017.07.792","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"4798_CR50","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/j.jacc.2013.05.069","volume":"62","author":"M Huelsmann","year":"2013","unstructured":"Huelsmann M, Neuhold S, Resl M et al (2013) PONTIAC (NT-proBNP selected prevention of cardiac events in a\u00a0population of diabetic patients without a\u00a0history of cardiac disease): a\u00a0prospective randomized controlled trial. J\u00a0Am Coll Cardiol 62(15):1365\u20131372. \n                    https:\/\/doi.org\/10.1016\/j.jacc.2013.05.069","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"4798_CR51","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","volume":"379","author":"L Bowman","year":"2018","unstructured":"Bowman L, Mafham M, Wallendszus K et\u00a0al (2018) Effects of aspirin for primary prevention in persons with diabetes mellitus. N\u00a0Engl J Med 379(16):1529\u20131539. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1804988","journal-title":"N Engl J Med"},{"issue":"21","key":"4798_CR52","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1001\/jama.2014.15825","volume":"312","author":"JB Muhlestein","year":"2014","unstructured":"Muhlestein JB, Lappe DL, Lima JA et al (2014) Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinical trial. JAMA 312(21):2234\u20132243. \n                    https:\/\/doi.org\/10.1001\/jama.2014.15825","journal-title":"JAMA"},{"issue":"8","key":"4798_CR53","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1093\/ehjci\/jey014","volume":"19","author":"OF Clerc","year":"2018","unstructured":"Clerc OF, Fuchs TA, Stehli J et al (2018) Non-invasive screening for coronary artery disease in asymptomatic diabetic patients: a\u00a0systematic review and meta-analysis of randomised controlled trials. Eur Heart J Cardiovasc Imaging 19(8):838\u2013846. \n                    https:\/\/doi.org\/10.1093\/ehjci\/jey014","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"7258","key":"4798_CR54","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","volume":"321","author":"IM Stratton","year":"2000","unstructured":"Stratton IM, Adler AI, Neil HA et\u00a0al (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321(7258):405\u2013412","journal-title":"BMJ"},{"issue":"12","key":"4798_CR55","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1136\/hrt.2003.020842","volume":"90","author":"H Bibra von","year":"2004","unstructured":"von Bibra H, Hansen A, Dounis V et al (2004) Augmented metabolic control improves myocardial diastolic function and perfusion in patients with non-insulin dependent diabetes. Heart 90(12):1483\u20131484. \n                    https:\/\/doi.org\/10.1136\/hrt.2003.020842","journal-title":"Heart"},{"issue":"11","key":"4798_CR56","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1007\/s00125-009-1470-0","volume":"52","author":"G Control","year":"2009","unstructured":"Control G, Turnbull FM, Abraira C et\u00a0al (2009) Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 52(11):2288\u20132298. \n                    https:\/\/doi.org\/10.1007\/s00125-009-1470-0","journal-title":"Diabetologia"},{"issue":"11","key":"4798_CR57","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.2337\/db09-0618","volume":"58","author":"PD Reaven","year":"2009","unstructured":"Reaven PD, Moritz TE, Schwenke DC et al (2009) Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis. Diabetes 58(11):2642\u20132648. \n                    https:\/\/doi.org\/10.2337\/db09-0618","journal-title":"Diabetes"},{"issue":"9958","key":"4798_CR58","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1016\/S0140-6736(14)60611-5","volume":"384","author":"HC Gerstein","year":"2014","unstructured":"Gerstein HC, Miller ME, Ismail-Beigi F et al (2014) Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial. Lancet 384(9958):1936\u20131941. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(14)60611-5","journal-title":"Lancet"},{"issue":"21","key":"4798_CR59","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1001\/archinternmed.2010.409","volume":"170","author":"R Roussel","year":"2011","unstructured":"Roussel R, Travert F, Pasquet B et\u00a0al (2011) Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med 170(21):1892\u20131899","journal-title":"Arch Intern Med"},{"issue":"11","key":"4798_CR60","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.2337\/dc07-0717","volume":"30","author":"E Erdmann","year":"2007","unstructured":"Erdmann E, Charbonnel B, Wilcox RG et\u00a0al (2007) Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care 30(11):2773\u20132778. \n                    https:\/\/doi.org\/10.2337\/dc07-0717","journal-title":"Diabetes Care"},{"issue":"1","key":"4798_CR61","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/S0195-668X(03)00468-8","volume":"25","author":"M Hanefeld","year":"2004","unstructured":"Hanefeld M, Cagatay M, Petrowitsch T et al (2004) Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart\u00a0J 25(1):10\u201316","journal-title":"Eur Heart J"},{"issue":"18","key":"4798_CR62","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.114.010389","volume":"130","author":"BM Scirica","year":"2014","unstructured":"Scirica BM, Braunwald E, Raz I et al (2014) Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 130(18):1579\u20131588. \n                    https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.010389","journal-title":"Circulation"},{"issue":"2","key":"4798_CR63","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1001\/jamacardio.2016.0103","volume":"1","author":"DK McGuire","year":"2016","unstructured":"McGuire DK, Van de Werf F, Armstrong PW et\u00a0al (2016) Association between sitagliptin use and heart failure hospitalization and related outcomes in type 2 diabetes mellitus: secondary analysis of a\u00a0randomized clinical trial. JAMA Cardiol 1(2):126\u2013135. \n                    https:\/\/doi.org\/10.1001\/jamacardio.2016.0103","journal-title":"JAMA Cardiol."},{"issue":"4","key":"4798_CR64","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N\u00a0Engl J Med 375(4):311\u2013322. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1603827","journal-title":"N Engl J Med"},{"issue":"19","key":"4798_CR65","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A et\u00a0al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N\u00a0Engl J Med 375(19):1834\u20131844. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"issue":"10157","key":"4798_CR66","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez AF, Green JB, Janmohamed S et al (2018) Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (harmony outcomes): a\u00a0double-blind, randomised placebo-controlled trial. Lancet 392(10157):1519\u20131529. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(18)32261-X","journal-title":"Lancet"},{"issue":"5","key":"4798_CR67","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1001\/jama.2016.10260","volume":"316","author":"KB Margulies","year":"2016","unstructured":"Margulies KB, Hernandez AF, Redfield MM et\u00a0al (2016) Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 316(5):500\u2013508. \n                    https:\/\/doi.org\/10.1001\/jama.2016.10260","journal-title":"JAMA"},{"issue":"1","key":"4798_CR68","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/ejhf.657","volume":"19","author":"A Jorsal","year":"2017","unstructured":"Jorsal A, Kistorp C, Holmager P et al (2017) Effect of liraglutide, a\u00a0glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail 19(1):69\u201377. \n                    https:\/\/doi.org\/10.1002\/ejhf.657","journal-title":"Eur J Heart Fail"},{"issue":"22","key":"4798_CR69","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM et\u00a0al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N\u00a0Engl J Med 373(22):2117\u20132128. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"issue":"12","key":"4798_CR70","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1007\/s00125-018-4729-5","volume":"61","author":"MJ Davies","year":"2018","unstructured":"Davies MJ, D\u2019Alessio DA, Fradkin J et\u00a0al (2018) Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 61(12):2461\u20132498. \n                    https:\/\/doi.org\/10.1007\/s00125-018-4729-5","journal-title":"Diabetologia"}],"container-title":["Herz"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-019-4798-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00059-019-4798-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-019-4798-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T00:27:42Z","timestamp":1584664062000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00059-019-4798-3"}},"subtitle":["Diagnostic challenge in type\u00a02 diabetes","Diagnostische Herausforderung bei Typ-2-Diabetes"],"short-title":[],"issued":{"date-parts":[[2019,3,21]]},"references-count":70,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["4798"],"URL":"https:\/\/doi.org\/10.1007\/s00059-019-4798-3","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,21]]},"assertion":[{"value":"21 March 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical guidelines"}},{"value":"P.\u00a0Valensi has received speaker fees from Abbott, AstraZeneca, Bayer, Eli-Lilly, GlaxoSmithKline, Merck Sant\u00e9, Merck-Sharp Dohme, Novo-Nordisk, Pierre Fabre and Sanofi-Aventis, research grants from Abbott, AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Merck Sant\u00e9, Merck-Sharp Dohme and Novo-Nordisk, and reports participation in Experts Committees for Abbott, Amgen, AstraZeneca, Boehringer-Ingelheim, Daichi-Sankyo, GlaxoSmithKline, Kowa, Merck-Sharp Dohme, Novo-Nordisk, Sanofi-Aventis. C.\u00a0Meune has received speaker fees from Bayer, Biom\u00e9rieux, Bristol Myers Squibb, Novartis, Roche Diagnostics and reports participation in Experts Committees for Bayer, Biom\u00e9rieux, Servier, Novartis, Roche Diagnostics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this article no studies with human participants or animals were performed by any of the authors. All cited studies were performed in accordance with the ethical standards indicated in each publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}